查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1971521

分支狹窄病變市場－全球產業規模、佔有率、趨勢、機會、預測：按應用、地區和競爭格局分類，2021-2031年

Bifurcation Lesions Market - Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Application (Peripheral, Coronary), By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 181 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球分叉病變市場預計將從 2025 年的 27.6 億美元成長到 2031 年的 40.1 億美元，複合年成長率為 6.42%。

冠狀動脈分叉病變的特徵是位於冠狀動脈主要側支起始部附近的複雜動脈狹窄，通常會涉及這些側支。全球市場擴張的主要驅動力是複雜冠狀動脈疾病盛行率的上升以及人口老化對先進心血管護理的需求。此外，介入性心臟病學領域的快速技術進步，例如藥物釋放型支架的改進和專用分叉器械的引入，透過改善手術效果並促進從傳統搭橋手術向微創技術的轉變，也推動了市場成長。

市場概覽
預測期 2027-2031
市場規模：2025年 27.6億美元
市場規模：2031年 40.1億美元
複合年成長率：2026-2031年 6.42%
成長最快的細分市場 周邊設備
最大的市場 北美洲

根據美國心臟協會引用的一項2024年核心實驗室評估，45.2%的三支血管冠狀動脈疾病患者至少存在一處真正的分叉病變。儘管患病率如此之高，但由於此類介入治療的固有技術挑戰，市場仍面臨著巨大的障礙。複雜的解剖結構通常需要先進的支架留置技術，與標準手術相比，這可能導致較低的成功率和更高的長期不利事件風險，例如支架內血管再阻塞和血栓症。

市場促進因素

冠狀動脈疾病和複雜病變在全球範圍內的日益普遍是推動全球分叉病變市場發展的主要因素。隨著老年人族群心血管疾病發生率的上升，治療性介入以解決複雜解剖閉塞的需求也日益成長。根據美國心臟協會 (AHA) 於 2024 年 1 月發布的《2024 年心血管和中風統計更新》顯示，目前約有 1.269 億美國人患有某種形式的心血管疾病，這一數字令人震驚。如此龐大的患者群體迫使醫療機構優先採用先進的導管介入技術，從而推動了商業活動的發展，美Medtronic力公司截至 2024 年 5 月的會計年度財務業績（其心血管產品組合的年收入為 118.31 億美元）便印證了這一點。

專用分叉支架系統的技術創新同樣至關重要，它從根本上改變了治療環境，提高了手術的安全性和有效性。該行業正迅速從臨時支架置入轉向整合先進的專用器械和高解析度成像技術，從而克服了進入側支血管的技術難題。隨著醫院更新設備，這種發展正在推動市場滲透。例如，波士頓科學公司在2024年1月的財報中報告稱，心血管業務銷售額成長了13.9%，這主要歸功於現代介入療法的應用。這些財務指標表明，技術進步使臨床醫生更有信心地進行複雜的經皮冠狀動脈介入治療。

市場挑戰

分叉病變治療固有的技術複雜性對全球分叉病變市場構成重大障礙。這些病變中常見的解剖異常往往會阻礙支架的最佳擴張和黏附，給介入性心臟病專家帶來挑戰。這種複雜性導致手術成功率存在差異，限制了採用新型、更昂貴的分叉病變專用器械所需的廣泛可靠性。當臨床醫生預期技術失敗或長期併發症的風險較高時，他們就不太願意對複雜病例採用經皮冠狀動脈介入治療，最終限制了整體的潛在市場需求。

根據美國心臟學會2024年發表的臨床數據，接受標準血管造影術經皮冠狀動脈介入治療（PCI）治療複雜分叉病變的患者，兩年內發生重大心血管事件的機率高達14.1%。如此高的併發症發生率，包括目標病變血管重組和心肌梗塞，進一步加深了人們對此手術風險的認知。因此，持續存在的安全隱患阻礙了市場成長，人們傾向於選擇保守治療或外科手術，而不是積極地對高風險解剖結構應用導管介入策略。

市場趨勢

血管內影像技術，特別是血管內超音波（IVUS）和光學同調斷層掃描（OCT）的廣泛應用，正在從根本上改變分支病變的治療方式。臨床醫生日益認知到，僅靠血管造影術往往不足以評估主幹和側支血管複雜的解剖結構，因此輔助影像技術在最佳化支架尺寸和黏附性方面的應用激增。這種轉變對於最大限度地減少支架失敗和提高長期血管通暢性至關重要。為了反映這一需求，波士頓科學公司在其2025會計年度財報中公佈，其心血管部門（包括先進的多重模式導航系統）的有機淨銷售額年增27.4%。

同時，秉持著「不留任何後遺症」的治療理念，藥物釋放型球囊（DCB）在側支血管治療中的應用正在迅速擴展。此策略透過將抗增殖藥物直接輸送至血管壁來解決血管再阻塞，無需在側支血管中留下永久性金屬植入，保留了未來的治療選擇。隨著越來越多的臨床證據支持其在複雜解剖結構中的安全性和有效性，這種方法正日益受到關注。例如，2025年5月《心血管商業》（Cardiovascular Business）雜誌的報導報道，Prevail DCB在複雜冠狀動脈疾病患者中實現了7.4%的2年靶病變血運重建率，凸顯了其不斷擴大的臨床效用。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球分支與狹窄市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 透過應用（周邊血管、冠狀動脈）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美分支狹窄病變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲分支狹窄市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區分支血管狹窄市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章 中東和非洲分支和狹窄病變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲分支血管狹窄病變市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球分支狹窄市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Boston Scientific Corp.
  • Abbott Laboratories Inc.
  • Cardinal Health Inc.
  • Medtronic Plc
  • CR Bard, Inc
  • Johnson & Johnson Services, Inc.
  • Spectranetics Corp
  • Terumo Medical Corp.
  • Poseidon Medical Inc

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 22390

The Global Bifurcation Lesions Market is projected to expand from USD 2.76 billion in 2025 to USD 4.01 billion by 2031, reflecting a compound annual growth rate of 6.42%. Coronary bifurcation lesions are characterized as complex arterial stenosis located near, and often involving, the origin of a major side branch within the coronary vessels. This global market expansion is primarily fueled by the rising prevalence of complex coronary artery disease and an aging population necessitating advanced cardiovascular care. Additionally, rapid technological advancements in interventional cardiology, such as the improvement of drug-eluting stents and the launch of specialized bifurcation devices, are bolstering market growth by improving procedural outcomes and encouraging a shift from traditional bypass surgery to minimally invasive techniques.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.76 Billion
Market Size 2031USD 4.01 Billion
CAGR 2026-20316.42%
Fastest Growing SegmentPeripheral
Largest MarketNorth America

According to a 2024 core laboratory assessment cited by the American Heart Association, 45.2% of patients with three-vessel coronary artery disease presented with at least one true bifurcation lesion. Despite this substantial prevalence, the market encounters a major obstacle due to the inherent technical difficulty of these interventions. The complex anatomy frequently requires demanding stenting techniques, which can lead to lower success rates and an increased risk of long-term adverse events, such as in-stent restenosis or thrombosis, when compared to standard procedures.

Market Driver

The escalating global prevalence of Coronary Artery Disease and complex lesions serves as the primary catalyst for the Global Bifurcation Lesions Market. As cardiovascular morbidity increases, particularly among the aging demographic, the need for interventions to address difficult anatomical blockages becomes more frequent. The burden is significant; the American Heart Association's "2024 Heart Disease and Stroke Statistics Update" from January 2024 notes that approximately 126.9 million Americans are currently living with some form of cardiovascular disease. This immense patient volume compels healthcare providers to prioritize advanced catheterization capabilities, driving commercial activity as evidenced by Medtronic's May 2024 financial results, which reported $11.831 billion in annual revenue for their Cardiovascular Portfolio.

Technological innovations in dedicated bifurcation stent systems are equally vital, fundamentally reshaping the treatment landscape by enhancing procedural safety and efficacy. The industry is moving rapidly from provisional stenting toward sophisticated, purpose-built devices and the integration of high-resolution imaging to overcome the technical difficulties of side-branch access. This evolution drives market uptake as hospitals modernize their inventories; for instance, Boston Scientific reported a 13.9% increase in Cardiovascular segment sales in their January 2024 financial results, attributed largely to the adoption of modern interventional therapies. These financial indicators demonstrate how technical progress empowers clinicians to perform complex percutaneous coronary interventions with greater confidence.

Market Challenge

The inherent technical complexity involved in treating bifurcation lesions acts as a significant barrier to the Global Bifurcation Lesions Market. The anatomical irregularities typical of these lesions often hinder optimal stent expansion and apposition, creating a difficult environment for interventional cardiologists. This complexity results in variable procedural success rates and limits the widespread confidence necessary to adopt newer, premium bifurcation-specific devices. When operators anticipate a high likelihood of technical failure or long-term complications, they are less inclined to utilize percutaneous coronary intervention for complex cases, thereby restricting the market's total addressable volume.

Clinical data highlighted by the American College of Cardiology in 2024 revealed that patients undergoing standard angiography-guided percutaneous coronary intervention for complex bifurcation lesions experienced a major adverse cardiac event rate of 14.1% over a two-year period. This high incidence of complications, including target lesion revascularization and myocardial infarction, reinforces the perception of risk associated with these procedures. Consequently, persistent safety concerns impede market growth by discouraging the aggressive application of catheter-based strategies in favor of conservative management or surgical alternatives for high-risk anatomies.

Market Trends

The widespread integration of intravascular imaging modalities, specifically Intravascular Ultrasound (IVUS) and Optical Coherence Tomography (OCT), is fundamentally transforming bifurcation lesion management. Clinicians increasingly recognize that angiography alone is often inadequate for assessing the complex anatomy of main and side branches, prompting a surge in the use of adjunctive imaging to optimize stent sizing and apposition. This shift is essential for minimizing stent failure and improving long-term vessel patency; reflecting this demand, Boston Scientific's February 2025 financial results reported that its Cardiovascular segment, including advanced multi-modality guidance systems, achieved an organic net sales growth of 27.4% compared to the prior year.

Simultaneously, the utilization of Drug-Coated Balloons (DCB) for side branch interventions is growing rapidly, supported by the "leave nothing behind" therapeutic philosophy. This strategy addresses in-stent restenosis by delivering anti-proliferative medication directly to the vessel wall without leaving a permanent metal implant in the side branch, thus preserving future treatment options. The approach is gaining traction as new clinical evidence confirms its safety and efficacy for complex anatomies. For example, an article in Cardiovascular Business from May 2025 noted that the Prevail DCB demonstrated a favorable two-year target lesion revascularization rate of 7.4% in patients with complex coronary artery disease, highlighting its expanded clinical utility.

Key Market Players

  • Boston Scientific Corp.
  • Abbott Laboratories Inc.
  • Cardinal Health Inc.
  • Medtronic Plc
  • C. R. Bard, Inc
  • Johnson & Johnson Services, Inc.
  • Spectranetics Corp
  • Terumo Medical Corp.
  • Poseidon Medical Inc

Report Scope

In this report, the Global Bifurcation Lesions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bifurcation Lesions Market, By Application

  • Peripheral
  • Coronary

Bifurcation Lesions Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bifurcation Lesions Market.

Available Customizations:

Global Bifurcation Lesions Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bifurcation Lesions Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Application (Peripheral, Coronary)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America Bifurcation Lesions Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Application
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Bifurcation Lesions Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Application
    • 6.3.2. Canada Bifurcation Lesions Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Application
    • 6.3.3. Mexico Bifurcation Lesions Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Application

7. Europe Bifurcation Lesions Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Application
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Bifurcation Lesions Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Application
    • 7.3.2. France Bifurcation Lesions Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Application
    • 7.3.3. United Kingdom Bifurcation Lesions Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Application
    • 7.3.4. Italy Bifurcation Lesions Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Application
    • 7.3.5. Spain Bifurcation Lesions Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Application

8. Asia Pacific Bifurcation Lesions Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Application
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Bifurcation Lesions Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Application
    • 8.3.2. India Bifurcation Lesions Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Application
    • 8.3.3. Japan Bifurcation Lesions Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Application
    • 8.3.4. South Korea Bifurcation Lesions Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Application
    • 8.3.5. Australia Bifurcation Lesions Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Application

9. Middle East & Africa Bifurcation Lesions Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Application
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Bifurcation Lesions Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Application
    • 9.3.2. UAE Bifurcation Lesions Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Application
    • 9.3.3. South Africa Bifurcation Lesions Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Application

10. South America Bifurcation Lesions Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Application
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Bifurcation Lesions Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Application
    • 10.3.2. Colombia Bifurcation Lesions Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Application
    • 10.3.3. Argentina Bifurcation Lesions Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Bifurcation Lesions Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Boston Scientific Corp.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Abbott Laboratories Inc.
  • 15.3. Cardinal Health Inc.
  • 15.4. Medtronic Plc
  • 15.5. C. R. Bard, Inc
  • 15.6. Johnson & Johnson Services, Inc.
  • 15.7. Spectranetics Corp
  • 15.8. Terumo Medical Corp.
  • 15.9. Poseidon Medical Inc

16. Strategic Recommendations

17. About Us & Disclaimer